Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LEXG-Lexicon Genetics -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (199)	9/6/2006 8:14:04 AM
From: nigel bates	Respond to of 254

Lexicon Genetics Initiates Phase 1 Clinical Trial of LX6171 for Cognitive Disorders Wednesday September 6, 7:30 am ET THE WOODLANDS, Texas, Sept. 6 /PRNewswire-FirstCall/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - News) announced today that it has initiated a Phase 1 clinical trial for LX6171, a novel, orally administered small molecule compound for cognitive disorders. The trial initiation follows the clearance in July of Lexicon's Clinical Trial Authorization (CTA) filing for LX6171 by the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). The Phase 1 clinical trial of LX6171 is being conducted in normal healthy volunteers to evaluate LX6171's safety, tolerability and pharmacokinetics. The trial is designed as a randomized, double-blind, ascending single dose study and is expected to include approximately 40 subjects. This trial will be followed by a randomized, double-blind, ascending multiple dose study of similar size. LX6171 is a selective and potent inhibitor of a novel membrane protein that is expressed exclusively in the central nervous system and is associated with synaptic vesicles and presynaptic membranes. It resulted from Lexicon's internal target and drug discovery efforts. In preclinical studies, LX6171 demonstrated improved learning and memory in healthy and aged mice. Lexicon is developing LX6171 for potential application in the treatment of cognitive disorders such as Alzheimer's disease, schizophrenia, vascular dementia, attention deficit disorder and Fragile X syndrome. "The commencement of human clinical trials for LX6171 marks the advancement of Lexicon's pipeline of drug discovery programs into development," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Lexicon. "Our internal research and discovery capabilities enable us to develop compounds, such as LX6171, that modulate novel targets and have the potential to address major areas of unmet medical need." About Lexicon Genetics Lexicon Genetics is a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs addressing these targets. For targets that the company believes have high pharmaceutical value, it engages in programs for the discovery and development of small molecule, antibody and protein drugs. Lexicon has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. Lexicon is working both independently and through collaborations and strategic alliances to accelerate the development and commercialization of its discoveries.